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ABSTRACT
Innovators appear unable to capture as much benefit from their
innovations as they--and society--might wish. This paper explores
the problem by identifying and examining the mechanisms used by inno-
vators to capture innovation benefit for themselves and to allocate
innovation-related costs to others. Only a few weakly and unevenly
functioning mechanisms are found serving these purposes in the U.S.
economy. Improvements are proposed which government and innovating
firms could undertake to increase innovators' returns from innovation.
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INTRODUCTION
Firms find it worthwhile to develop new products and processes when
their benefits exceed their costs by a margin they find attractive. But
attractive cost benefit ratios are not immutable characteristics of
particular innovations: they are created by an innovating firm's ener-
getic strivings to capture innovation-related benefits for itself and to
allocate innovated-related costs to others.
Innovating firms are not as successful at creating attractive inno-
vation cost benefit ratios as society might wish. As recent research by
Mansfield et al. (1) and two others (2,3) finds (see Table 1), firms'
"private" rates of return from innovation (net return to the innovating
firm) are much lower than "social" rates of return from innovation (net
return to the innovator plus net return to all other private parties--
innovation users, suppliersimitators, etc.--affected by the innovation).
INSERT TABLE 1 HERE
This result suggests the unfortunate possibility that many innovations which
would pay handsome social returns are not being carried out because the
private rates of return to the innovating firm are unattractive. It would
thus behoove us to identify and explore the nature of the mechanisms which
firms currently use to capture innovation benefit and allocate innovation
costs, and to consider how these might be improved by industry and govern-
ment. To my knowledge, such an exploration has not been carried out before,
and we will often find ourselves treading new ground.
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Table 1
SOCIAL AND PRIVATE RATES OF RETURN*
FROM INVESTMENT IN INNOVATION
Study: Mansfield et al. (1) Tewksbury et al. (2) Nathan Associates (3)
Social Private Social Private Social Private
Median %; 56 25 99 27 70 36
Range %: Neg-307 Neg-214 Neg-472 Neg-148 Neg-371 Neg-157
Sample n: 17 20 20
*Note: All three studies utilize Mansfield's definitions of private and
social rates of return. In brief, Mansfield defines private returns
as net pretax profit of the innovating company minus RD costs and
other innovation-related investment minus profits (such as profits
from sales of products displaced by the innovative product) lost as
a result of the innovation. Social returns are defined as private
returns plus innovation-related benefits and costs incurred by all
innovation users and firms which compete with the innovator plus the
impact, if any, of the innovation on public goods such as water
quality. Note that Mansfield's measure of social return is incom-
plete, since it excludes innovation-related returns experienced by
suppliers, independent inventors and others. These omissions have
an appropriately conservative effect given the direction of his
findings.
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A TAXONOMY OF INNOVATION BENEFIT CAPTURE MECHANISMS
Many means exist by which firms may gain competitive advantage, rang-
ing from superior management, marketing, or production skills to favorable
access to financial and other resources. Almost all of these means are
innovation independent, however: they will serve innovators and imitators
equally. The only mechanisms which will give an innovator advantage over
imitators are those which give him some degree of monopoly control over his
innovation, control which he can use to charge license fees or to exclude
would-be imitators and produce in-house under favorable market conditions,
thus recouping his innovation investment. Without such control, part of
the costs incurred by an innovator can be avoided by an imitator because he
can freely learn what the innovator has spent money to learn. And under
such conditions it would pay firms to imitate rather than innovate--obviously
not a socially desirable result.
It is a rather difficult to devise mechanisms which allow innovators some
effective degree of monopoly control over their innovations, because at
bottom one is trying to control the diffusion of innovation-related know-
ledge. I have been able to identify three such mechanisms currently extant
in our economy: patents, trade secrets lso called "know-how'), and lead
time.* Interestingly, while the patent grant and trade secrecy may be dis-
cussed as conscious social inventions, the lead time mechanism may best be
described as an aspect of our economic system which innovators have learned
to turn to advantage. As I will describe, each of the mechanisms operates
according to a different principle, allows protection of different types of
innovation knowledge, and provides the innovator with a greater or lesser
degree of freedom with respect to converting innovation control into innova-
tion benefit.
*Copyright protection, extended to computer software by Congress in December,
1980 via an amendment to the 1976 Cooyright Act, is not considered here,
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The Federal patent system grants a patentee temporary legal pro-
perty rights to publicly available knowledge--normally a free good. In
essence, it stipulates that, if the inventor will make knowledge of his
invention generally available by publishing it in a patent, society will
grant him the temporary legal right to prevent others from using that
knowledge and/or allow him to charge fees for its use.
The type of innovation-related knowledge which a patent grant is de-
signed to protect is severely limited. Protection is offered only to ex-
plicitly described technical means to achieving a useful end--given that
the means is of sufficient novelty and usefulness to be legally deemed an
invention. Thus, patents cannot be used to protect valuable technical
know-how not deemed sufficiently novel to constitute invention. Nor can
they be used to prevent free access by imitators to the very valuable non-
technical developments which an innovator must often invest in, such as
proving the existence of a market for a functionally new device and educa-
ting potential customers.
In contrast to the patent system's protection of publicly available
knowledge, innovators can protect their innovation-related trade secrets
from would-be imitators by keeping that knowledge secret. The possessor of
such a trade secret has an indefinite period of exclusive use of his in-
vention or discovery. State trade secret legislation allows him to keep
the information entirely secret or to make legally binding contracts with
others in which the secret is revealed in exchange for a fee or other con-
sideration and a commitment to keep the information secret. A trade secret
possessor may take legal steps to prevent its use by others if they can be
shown to have discovered the secret through unfair and dishonest means such
as theft or breach of a contract promising to keep it secret. Note, however,
that the possessor hs no property rights in the secret knowledge itself.
If an imitator discovers the secret by legal means such as reverse en-
gineering, the innovator has no recourse.
A legally protectable monopoly of indefinite duration is obviously a
very attractive mechanism for capturing innovation benefit. It is, however,
an option only for innovations which can in fact be kept secret. In prac-
tice, therefore, trade secrets have proven to be effective only with regard
to product innovations incorporating various technological barriers to
analysis, or with regard to process innovations which can be hidden from
public view,
There are, in the first instance, certain innovations embodied in pro-
ducts which, while sold in the open market and thus available for detailed
inspection by would-be imitators, manage nevertheless to defy analysis for
some technological reason and which cannot therefore be reverse engineered.
Complex chemical formulations sometimes fall into this category, the classic
case being the formula for Coca-Cola. Such barriers to analysis need not
be inherent in the product--they can sometimes be added on by design. Thus,
some electronic products gain some protection from analysis via use of a
packaging method C'potting") and packaging materials which cannot easily be
removed without destroying the proprietary circuit contained within. (4)
Methods for protecting trade secrets embodied in products accessible to com-
petitors need not be foolproof to be effective--they simply have to raise
enough of a barrier in a given case to create an unattractive cost benefit
equation for would-be imitators in that case.
In the second instance, process innovations such as novel catalysts
or process equipment can be protected effectively as trade secrets, whether
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or not they could be "reversed engineered" by a would-be imitator allowed
to examine them, simply because they can be exploited commercially while
shielded from such examination behind factory walls.
Finally, an innovator can use the lead time mechanism to temporarily
protect his innovation property rights. Lead time is the period which
starts when an innovator begins to make economic use of his innovation and
ends when the first imitator begins to compete. Even when an innovator
cannot protect himself via patent or secrecy, some lead time is always pre-
sent due to the response time of imitators, and lead time protection is
therefore potentially applicable to all innovators. It simply takes time to
decide to imitate and then to tool for productiondevelop marketing plans,
and do the other myriad things which must be done before any product, even
an imitative one, can be brought to the marketplace.
Although some amount of lead time is always available to an innovator,
the level of effective monopoly control it can provide him is heavily de-
pendent on several situation-specific factors. One such factor is the
length of lead time divided by length of customer purchase decision cycle.
A high value of this factor favors the innovator over imitators. Consider
one extreme example: a consumer "fad" item (very short purchase decision
time) which sells in high volume for six months only. Assume that the item
can be readily imitated--but can only be produced economically by mass-pro-
duction tooling requiring six months to build. Obviously, lead time here
allows the innovator to monopolize the entire market if he can supply it
with his initial tooling. At another extreme is an expensive capital equip-
ment innovation which customers typically take two years to decide to buy,
budget for, etc.--and which competitors can imitate in one year. Obviously,
lead time in this instance affords an innovator little protection. A second
Ill
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situationsspecific factor involves the slope of the learning curve. The
steeper the curve, the greater the production cost advantage an innovator
can accrue relative to potential imitators per unit of lead time enjoyed.
While innovators are trying to protect their innovations via the
mechanisms described above, would-be imitators are trying to defeat these
and gain free access, The actual protection an innovator achieves depends
on the outcome of this contest. Since numerous, often effective strategies
are known for attacking each mechanism, protection afforded is often low--
and always uncertain.
Imitators who wish to use an innovator's patented knowledge against
his will have several time-tested options. First, knowing that the patent
law, places the considerable burden of detecting and prosecuting infringers
on the patentee, imitators can simply infringe if they judge a particular
patentee unable or unwilling to defend his rights. If brought to court,
they may try to convince a court that the patent is invalid, and studies of
court statistics C5) show they often succeed in this even though under the
U,S, patent system claims are studied by employees of the Patent Office and
judged to be valid before a patent is granted. Second, imitators can try
to "invent around" a patent by modifying the invention in such a way as to
skirt the material specifically protected by the patent. Such inventing
around may well cost considerably less than the investment the innovator--and
society-_is trying to protect via the patent mechanism.
Empirical and anecdotal evidence (6) shows that that patent grant is
not a very effective innovation benefit capture mechanism in most fields of
technical endeavor, with pharmaceuticals and chemicals being the primary ex-
ceptions, Data shows innovators do not rely much on patent protection (7)
and gain little financial return from patents they attempt to license, (8)
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Would-be imitators use several means to gain access to innovator's
secret know-how. Products on the marketplace are the most vulnerable be-
cause methods of analysis are getting more sophisticated. In some industries,
notably semiconductors, certain companies specialize in circumventing the
technical barriers erected by innovators, analyzing and reverse engineering
the innovative product and selling the innovator's hard-won knowledge at a
low price to interested imitators. Sometimes secret process innovations will
also be discoverable by analyzing the chemical or mechanical traces left in
the manufactured product output (we find traces of x solvent in the plastic
so they must have developed x process; the mold marks left on the product
indicate a novel mold was used of construction z) or by noticing unusual inputs
to the factory containing the secret process (why are they buying so much
platinum?). More often, however, such process secrets are eventually revealed
by people who shared in the secret of the innovating company and then left.
If such breaches of confidence can be traced and proven, the innovating
company can sue and enjoin the resulting imitation, but often the evidence
is not so clear.
Finally, an innovation's lead time is also potentially vulnerable to the
efforts of would-be imitators. Such firms can attempt to shorten an innova-.
tor's lead time by being alert to early signs of an innovator's plans such
as orders of special parts from suppliers and test market experiments. In
the consumer product field, some firms even make a business of observing
innovator's test markets and reporting the results to interested competitors
for a fee.
Conversion of Control into Benefit
An innovator who has succeeded in thwarting the attacks of would-be
imitators and has established some degree of monopoly control over his
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innovation has another task to perform--the conversion of control into
innovation benefit. As in the case of establishing control, this is not
an orderly process--and not all types of innovators find themselves
created equal with respect to it.
As was observed earlier, an innovator can in principle capture bene-
fit from his innovation either by licensing it or by producing the innova-
tive product (using the innovative process) in his own firm. In the former
case, the innovator uses his monopoly power to exact a fee from those he
licenses--and to exclude those he does not license. In the latter case,
he uses his monopoly power to exclude all competitors and thereby increases
the innovation-related sales and/or profits of his own firm above what would
otherwise be attainable. Since, for a given innovation, maximum private
innovation return may come from a policy of in-house exploitation by the
innovator only, licensing to other firms only, or a combination of these,
the perfect innovation benefit capture mechanism would provide monopoly con-
trol effective for either strategy. In fact, only the patent mechanism
approaches this ideal--for the type of knowledge protected by a patent.
Know-how and lead time protect in-house exploitation of an innovation far
more effectively than they protect the innovation property rights of an
innovator who wishes to license. The reason for this difference is clear--
and the consequences are significant.
In order to license innovation knowledge, an innovator must be able
to display it to potential licensees without thereby losing his innovation
property rights. If his protection comes via a patent grant, he can publi-
cize his innovation with impunity: The patent protects public knowledge.
In contrast, his ability to display trade secrets to potential licensees
' 
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is sharply limited because, as the reader will recall, the trade secret
mechanism protects only secret knowledge--and a secret cannot be shared
very widely and remain a secret. Finally, the leadtime mechanism cannot
be used at all for licensing because it involves no proprietary control of
knowledge. It can only protect an innovator's own direct, in-house ex-
ploitation of his innovation.
The relative lack of protection for innovators who wish to license
their innovations creates a bias in favor of direct in-house exploitation
of an innovation by an innovator. Since all would-be innovators are not
equally able to exploit a given innovation in-house, the significant con-
sequence is that some innovators are better positioned to convert their
monopoly control of a given innovation into a private innovation benefit
than are others.
For example, firms with more resources to invest would be better posi-
tioned than poorer firms to exploit innovations which require high invest-
ment. So too would firms who find they already have some of the needed
resources--such as special production facilities or distribution channels
or reputation in the market--in place.
On the other end of the scale, independent inventors will be uniquely
poorly positioned to convert monopoly control to innovation benefit when
that monopoly control applies to protection of in-house use only.
Note that in many industries, especially fragmented ones, all existing
firms may have a relatively poor ability to capture benefit via in-house
exploitation of an innovation. And in such industries, one can expect the
industry's incentive to innovate--and innovation record--to suffer from the
relative inability of existing innovation benefit capture mechanisms to
protect innovators who wish to license.
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A TAXONOMY OF COST ALLOCATION MECHANISMS
To this point I have examined mechanisms by which innovators can cap-
ture innovation benefit--but private rates of return on innovation invest-
ment can be increased by improving the ability of the innovating firm to
allocate its innovation costs to others as well, and I now turn briefly to
a taxonomy of mechanisms to achieve this end. I will consider first the
mechanisms which innovators use to allocate innovation costs to users and
suppliers, then those applied to allocate costs to competitors, and finally
those applied to government.
Innovating firms gain their power to allocate innovation costs to some
suppliers and users through their power to choose whom to buy from and their
power to set some conditions of sale. An innovating firm's allocation of
innovation costs to high benefit users usually takes the form of requests for
innovation-related payments of various types such as payments for "tooling"
and for "development." In contrast, cost sharing with suppliers usually in-
volves the supplier shouldering some of the development work involved in the
innovation project. Thus, suppliers are often asked to do some or all of the
design work on components they will supply to the innovating firm, and are
sometimes asked to design other components as well or to provide other "tech-
nical assistance."
Cost sharing agreements are made between innovating firms and individual
users and suppliers. An innovator is most likely to be able to make such
agreements if his innovation is one which brings high benefit to individual
user or supplier firms--as opposed, for example, to bringing a little bene-
fit to each of many firms in a fragmented market. Further, such high benefit
users and suppliers are most likely to cost share if they gain some commen-
surate advantage from it which is not available to their free-riding compet-
aa _  _ _
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itors. Thus, user's willingness to cost share may be contingent upon re-
ceiving favored treatment with respect to delivery times while a supplier
may expect to receive production orders for a part in exchange for designing
it. Such expectations are often not legally enforceable--for example, a
supplier usually has no legal means of preventing an innovating firm from
placing production orders for the part he has designed with others. Indeed,
the only pragmatic constraint on such behavior is usually an innovating firm's
fear that not giving preferential treatment to cost-sharing users and suppliers
will result in less help being offered on their next project.
Innovators sometimes share development costs and/or work with their com-
petitors via joint agreements. Such agreements can be limited to a specific
project but are often for an open-ended program of industry-relevant research
to be conducted by a jointly funded "Industrial Research Association." The
recent, reportedly fruitful, joint research effort by a group of Japanese semi-
conductor firms in the area of VLSI Processing technology appears to have
triggered some interest in the concept in the U.S., and the Justice Depart-
ment has recently responded by issuing guidelines indicating that, under many
conditions, research sharing between competitors would not violate existing
antitrust laws. Such research sharing is not new, however, and the historical
record does not show the concept very vital. Despite long-term government
funding and support, for example, the proportion of a given industry's RD
performed in British Industrial Research associations was only 1-3% of total
industrial RD effort in such research intensive industries as electrical en-
gineering and chemicals (9) and tended to be focused on matters such as stand-
ards setting rather than novel products or processes. The proportion of in-
dustry RD expenditure performed in Industry Associations was also relatively
small in other European countries (10) and also felt to be unimportant in Japan (11).
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Research cost and/or work sharing between potential competitors is un-
likely to prove a more vital innovation cost allocation mechanism in the
future for a simple reason: As was not the case when one shares costs with
users or suppliers, the quid pro quo for sharing innovation cost with one's
direct competitors is that one shares innovation knowledge. Thus competitors
are prevented from using that knowledge to competitive advantage--which is
usually its main source of benefit. Joint research can and does flourish
when providers of the same good or service are not direct competitors for
some reason, however. Thus, the electric utilities, each a geographic mono-
poly, logically cooperate in the Edison Electric Institute. Similarly,
patent pools on such technologies as the manufacture of petrochemicals often
thrive when there are strong barriers, such as control of feedstocks, which
prevent one firm from using innovation to invade another's market.
Government shares innovation costs in several ways--and via myriad spe-
cific programs. First, it is a buyer and user of many innovative goods and
services, and it will often share the cost of developing these much as buyers
in the private sector do. Thus, the Defense Department has paid for the de-
velopment of military aircraft, electronics, etc. Second, the government
implicitly recognizes that the ability of would-be innovators to capture pri-
vate return from basic research is low, and therefore undertakes to fund re-
search in university and industry laboratories, and to perform research in
government laboratories. Third, the government attempts to diffuse research
results to potential users via general data banks such as the National Tech-
nical Information Service (NTIS) as well as programs targeted to specific
user groups such as the Agricultural Extension Service. Fourth, it reduces
the cost of RD through special tax treatment for RD expenditures. Period-
ically, the government will decide that a particular area--energy is a good
current example--needs special stimulus and it may then shoulder a greater
  ---------- -- -- 1^-1----------1----------
IIIll
-13-
than usual amount of innovation costs in that area by, for example, funding
"demonstration plants" embodying a new technology. Obviously, the pattern
and level of government innovation cost sharing is set and reset as part of
the political process.
DISCUSSION
As a result of the examination of innovation benefit capture and cost
allocation mechanisms discussed, one can begin to appreciate the possibility
that benefit capture by innovators is not only in general too low, as is
suggested by the data collected by Mansfield and others, but that it varies
strongly from case to case and from industry to industry and causes related--
and not necessarily desirable--variations in the types and levels of innova-
tion undertaken in the U.S.
Given the importance of the issue, it would seem useful to explore the
area further. One research approach which seems promising in several regards
involves empirical studies of what I have termed the "functional locus of
innovation." I have summarized the findings of a few such studies in Table 2
and as the table shows, such studies have shown strong variations in the
sources of innovation. These are arguably (12) caused by major variations
INSERT TABLE 2 HERE
Table 2
EMPIRICAL DATA ON THE FUNCTIONAL SOURCE
OF INDUSTRIAL INNOVATIONS
Nature of Innovations and
Sample Selection Criteria
Computer innovations 1944-62:
- systems reaching new perform-
ance high
- systems with radical structur-
al innovations
All engineering polymers developed
in U.S. after 1955 with >10mm
pounds produced in 1975
Chemical activities for plastics:
All plasticizers and UV stabiliz-
ers developed post World War II for
use with 4 major polymers
Innovation Developeda by:
n User% Mfr%
143 25
18 33
75
67
6 0 100
16 0 100
von Hippel1 6
von Hippel1 7
Scientific instrument innovations:
- first of type (e.g., first NMR)
- major functional improvements
- minor functional improvements
Semiconductor and electronic sub-
assembly manufacturing equipment:
- first of type used in commercial
production
- major functional improvements
- minor functional improvements
Notes
aAttribution of an innovation to a user or manufacturer "developer" is
determined by which of these first builds and utilizes the innovation
in conformance with his economic function. Thus, attribution to a
user source is made if a user builds and uses an innovation before a
manufacturer builds and sells a commercial version. And conversely,
attribution to a manufacturer source is made if a manufacturer builds
and sells a commercial version of an innovation before a user builds
and uses a home-made version; NA data excluded from percentage.
bAttribute missing percentage to joint user-manufacturer innovation projects.
Study
Knight13
Bergerl4
BoydenIS
4 100
44 82
63 70
7 100
22 63
20 59
C
18
30 '
2b
21
29
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in the abilities of firms holding different functional relationships (e.g.,
user, supplier) to a given innovation to apply the different benefit capture
mechanisms which have been discussed to capture benefit from it (for example,
a user who develops an innovative process machine can protect it or a trade
secret while using it behind his factory walls. In contrast, a process
machine manufacturer who developed the same machine could not avail himself
of this form of protection from imitators: he must display the machine in
order to sell it). These differences can be used to empirically explore the
real-world effectiveness of extant benefit capture and cost allocation mech-
anisms, and work on this topic is in process.
All corrective action need not wait on further research, however, and I
now turn to consider some implications of what is currently known for govern-
ment and industry.
Implications for Government
Government is in the fortunate position of being able to devise and im-
prove mechanisms for innovation cost allocation and benefit capture. To this
point, it has focused almost exclusively on cost allocation mechanisms, and
I suggest that it is now time to devote effort to exploring and improving
benefit capture mechanisms.
In my view it is particularly important to make efforts to improve the
level of real world protection offered by the patent grant because, as we
observed earlier, it is in principle the most flexible of existing benefit
capture mechanisms, offering, as it does, protection for publicly available innovation-
related knowledge. Indeed, if a "perfect" patent mechanism could be devised which
gave an innovator "perfect," costlessly enforceable property rights to his
innovation, i.e., if, without cost to himself, he could totally control its
diffusion and capture benefit from innovation users, manufacturers, and
others to the point where adoption becomes a matter of indifference to these,
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then two very interesting things happen. First, any innovator could reap
the same amount of benefit from a given innovation* and, second, the inno-
vator could increase his private rate of return above the social rate of
return.** Since perfection is elusive in this as in all spheres, the
* The reasoning behind the above conclusion is that costless enforcement of
property rights would allow any innovator to set the fees charged to each
innovation beneficiary, and each class of beneficiaries, so as to attain
the maximum return. The role which the innovator himself happens to play
with regard to the innovation--user, manufacturer, etc.--does not influence
his fee-setting decision because he is equally able to capture innovation
returns from his own company and other companies. This being so, he has
no incentive to concentrate benefits in his own company. For this to
strictly hold, the assumption of costless enforcement of property rights is
required for the following reason: Since marketing of an innovation and
enforcement of payment can be reasonably assumed to be costless for an in-
novating firm when it captures output-embodied benefit by utilizing the in-
novation knowledge in its own processes and/or products, non-costless market-
ing of and enforcement of payments for use of innovation knowledge by other
firms would create a differential between benefit attainable from in-house
and external use of the innovation and generate a preference for the former.
This in turn would allow an incremental benefit from the same innovation to
accrue to those innovators with a larger in-house use for it.
Note that, with perfect, costlessly enforceable innovation property rights,
an innovator has no reason to give preference to his own firm's in-house
use of the innovation even if the direct return from the particular innovation
can be "leveraged" by its user. Suppose, for example, that a minor cost-re-
ducing process innovation were made available to one of several manufacturers
of a commodity with previously equal manufacturing costs, financial resources,
etc. If further innovations or other changes did not intervene, the commodity
producer benefiting from the innovation could in principle increase his market
share as a consequence of innovation and thus "leverage" the direct benefits
of the innovation, perhaps many fold. But note that, even under such a set
of circumstances, the innovator has no incentive to prefer to increase or de-
crease the market share of his own company relative to that of his competitors
because he can, given perfect information, also charge the benefiting company
for such second (and nth) order benefits arising from the innovation up to
the point of indifference.
** Recall that the social return from an innovation is the innovator's net
private return plus the net innovation-related return of all other affected
parties. If perfect, costlessly enforceable innovation property rights allow
the innovator to reduce the returns of all other affected parties to their
indifference point, the private rate of return will be above the social rate
of return (given, of course, that the weighted indifference rate of these
others lies below the private rate of return of the innovation at issue).

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important point is that improving the patent mechanism will have an effect
in the desired direction on the private rate of return and will also reduce
the discrepancy which currently exists between the ability of different
innovators to capture private benefit from a given innovation,
As we have discussed, the effectiveness of the patent mechanism is
currently low for two types of reason: First, because the type of knowledge
it protects is narrowly restricted to technical invention and, second, be-
cause protection of granted patent rights is uncertain and expensive, I
suggest that solutions be sought for both of these patent problems,. With
respect to the first we should experiment with expanding the protection
offered by patents to other forms of knowledge which. are currently free to
imitators, but which innovators must invest in so';as to obtain innovation
benefit, Consider, for example, the cost involved in defining the market for
a new-function product, Why should that innovation-related knowledge not be,
protected directly rather than indirectly via the (possible) technical novelty
of the means by which the effect is achieved? Similarly, why should one not
extend patent protection to the invention of a new. means of doing business and
other subject matters now not covered? (18) Second, the government should
make the assertion of one's patent grant rights less costly and uncertain than
it currently is., The recent revised patent law promises some help in this
direction by allowing th.e patent office to reexamine initial challenges to a
patent's validity administratively, rather than requiring that challengers pur-
sue the matter in court. This should allow some questions of patent validity
to be resolved more quickly and economically than heretofore, Many other pro-
blems, such as judges' apparent bias against the monopolies afforded by patents
(19), still have to be addressed however.
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Innovation benefit capture mechanisms can be designed to protect a
broad range of innovators, as in the case of the patent grant, or to reward
only a specified few. As an example of the latter type, consider a mechanism
in which the government offers a prize to the first to achieve a specified
innovation and make the knowledge freely available. Economists are fond of
this concept because, as they point out, innovation-related knowledge, once
created, has a very low reproduction cost and social returns from it would be
highest if all were given free access to it. (Note that the patent mechanism
insures less than optimal use because it arranges that the innovator will ob-
tain his return by charging a fee for use of his knowledge, thus making other-
wise marginally attractive uses of that knowledge uneconomic.) Clearly a prize
can call forth enormous effort--as the recent Kramer prize offered for the
achievement man-powered flight around a specified course shows. On the other
hand, this mechanism requires that some individual or group set the specifica-
tions for individual desired innovations, and appropriate levels of reward--
not a trivial task.
Next the government should strive to avoid taking actions which weaken
the effect of existing benefit capture mechanisms. For example, it should re-
view current policies regarding requirements for second sourcing for products
if it can economically meet its needs for security against interruption of
supply by, for example, carrying an inventory large enough to tide it over
until a new source can be initiated. The effect of demanding a second source
is to eliminate the lead time advantage of the first firm--and any lead time-
related incentive which that firm might have to innovate. As a second ex-
ample, it should be careful about demanding access to innovator's trade secrets--
as it has demanded of chemical firms under the Toxic Substances Cntrol Act (TSCA).
Given the central role played by know-how in many industries, the companies'
pleadings that crucial trade secrets are at risk is not to be taken lightly. (20)
 
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Finally, government should understand that innovation costs, benefits--
and work--are distributed differently in different industries, and should
develop an input-output table type of measure of RD expenditures versus
innovation sources to reflect this reality appropriately. Such a measure
would, for example, allow one to display the reality that scientists usually
resident in universities develop novel scientific instruments which instru-
ment manufacturers then produce. (16) Simpler measures which compare only
the RD expenditures versus innovation output of a given firm result in
significant distortion (for example, use of that measure in NSF's Science
Indicators 1976 gave rise to the predictable but misleading observation that
producers of professional and scientific instruments were relatively effi-
cient converters of RD dollars into scientific instrument innovations). (21)
Similarly, an input-output type measure would demonstrate the often-voiced
concern that the U.S. machine tool industry is too fragmented to support the
process machinery innovation needed to improve U.S. productivity is at least
partly wrongly framed by showing that much process machinery innovation is
carried out by machine tool users. (17)
Implications for Industry
In this paper we have seen that innovation-related costs and benefits
are distributed over users, manufacturers, suppliers, and others, and that
the level of private return achieved by the innovator depends on the outcome
of a struggle between the participants, waged with combinations of imperfect
benefit capture and cost allocation mechanisms. In principle, innovating
firms can enhance their private returns by discovering and exploiting new
mechanisms--as was done in the instance of lead time and cost allocation to
users and suppliers--or, more routinely, they may seek to improve the effi-
ciency with which they use existing mechanisms.
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Currently no hard information exists as to how firms might improve their
use of existing benefit capture mechanims. Anecdotal evidence of two sorts
suggests, however, that improvement is possible. First, while most firms
clearly understand their overall competitive strengths and weaknesses with
respect to other firms, and can articulate the strategies they have developed
to enhance the former and minimize the latter--almost no firm, in my exper-
ience, can articulate precisely how--or whether--it benefits to utilize avail-
able innovation benefit capture mechanisms. Second, the behavior of many
firms seems puzzling when viewed in terms of innovation benefit capture. For
example, some firms will openly display apparently valuable innovative process
know-how to competitors, while other firms will be quite secret about what,
upon inspection, seem to be rather generally known processing techniques.
Clearly, more research in this area would be interesting and useful.
The anecdotal evidence is slightly stronger with respect to the efficiency
with which innovating firms use existing cost allocation mechanisms. On the
one hand, firms appear to routinely use the mechanism of allocating innovation
costs to benefiting users and suppliers. Indeed, evidence of this activity
can sometimes be found in the public record--especially with respect to major
projects (for a recent example see (22)). On the other hand, firms have not
installed the analytical tools needed to routinize such cost allocations, and
this suggests that their efficiency in the area could be significantly improved.
Consider, for example, the fact that an innovating firm's RD staff seldom
makes an analysis to identify the benefits which a contemplated project might
bring to potential suppliers of components and materials. As a result, it is
not in a position to identify portions of the development work which competent
suppliers might be induced to undertake if asked. In the absence of such data,
present practice appears to be to simply assume that all relevant RD which
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can be done in-house will be, and that outside cost and/or work sharing
with suppliers will only be sought when in-house resources or expertise is
lacking. Obviously, opportunities to allocate costs to suppliers are missed
under such a regime, and obviously improvement should be possible.
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